Literature DB >> 15156266

Essential thrombocythemia-related acute ST-segment elevation myocardial infarction. A case report and literature review.

Samantapudi K Daya1, Ramesh M Gowda, William A Landis, Ijaz A Khan.   

Abstract

Essential thrombocythemia is a clonal disorder of the myeloid stem cell that causes pathologic expansion of the megakaryocytic elements in the bone marrow, with a persistent increase in the platelet count. The disease is associated with an elevated risk of thrombosis, hemorrhage, and vasomotor symptoms. The presenting features of essential thrombocythemia can range from being asymptomatic to thrombohemorrhagic complications including acute myocardial infarction. Acute ST-segment elevation myocardial infarction due to left main trunk and ostial left anterior descending coronary artery lesions was diagnosed in a young 31-year-old man. Platelet count was markedly increased and essential thrombocythemia was also diagnosed. Because of left main disease, primary coronary intervention was not feasible and an emergent coronary artery bypass grafting was performed along with pharmacologic management of essential thrombocythemia. The early postoperative period was complicated by acute pulmonary embolism. Hydroxyurea and anagrelide were administered postoperatively, resulting in the decrease of platelet count. A succinct review of myocardial infarction in patients with essential thrombocythemia is presented, and therapeutic strategies in such patients are discussed.

Entities:  

Mesh:

Year:  2004        PMID: 15156266     DOI: 10.1177/000331970405500312

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

1.  Left main coronary thrombosis with essential thrombocythemia.

Authors:  Zekeriya Nurkalem; Nevzat Uslu; Sevket Gorgulu; Mehmet Eren
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

2.  Off-pump myocardial revascularization in a high-risk patient with essential thrombocythemia.

Authors:  Ahmad K Darwazah; Hamad Madi; Rami Zagha; Yahia Hawash
Journal:  Tex Heart Inst J       Date:  2014-10-01

3.  Multiple culprit arteries in patients with ST segment elevation myocardial infarction referred for primary percutaneous coronary intervention.

Authors:  Peter M Pollak; Shailja V Parikh; Muhammed Kizilgul; Ellen C Keeley
Journal:  Am J Cardiol       Date:  2009-06-24       Impact factor: 2.778

4.  Challenges in the treatment of patients with essential thrombocythemia and acute coronary syndrome.

Authors:  Christina Doesch; Björn Krämer; Tobias Geisler; Andreas E May; Stefan-Martin Kroeber; Reinhard Kandolf; Meinrad Gawaz
Journal:  J Thromb Thrombolysis       Date:  2007-08-14       Impact factor: 2.300

5.  Postsplenectomy reactive thrombocytosis.

Authors:  Palwasha N Khan; Rajasree J Nair; Jairo Olivares; Leslie E Tingle; Zhiyong Li
Journal:  Proc (Bayl Univ Med Cent)       Date:  2009-01

6.  What is the meaning of P2Y12 reaction units in patients with essential thrombocythemia?

Authors:  Shinya Goto; Shinichi Goto
Journal:  J Cardiol Cases       Date:  2015-09-11

7.  Platelet Reactivity and Response to Aspirin and Clopidogrel in Patients with Platelet Count Disorders.

Authors:  Wiktor Kuliczkowski; Ewa Żurawska-Płaksej; Maria Podolak-Dawidziak; Magdalena Cielecka-Prynda; Bożena Karolko; Jakub Dębski; Konrad Kaaz; Marcin Protasiewicz; Iwona Prajs; Andrzej Mysiak; Tomasz Wróbel; Lidia Usnarska-Zubkiewicz
Journal:  Cardiol Res Pract       Date:  2021-04-17       Impact factor: 1.866

8.  Case Report: A Rare Case of Acute Anterior Myocardial Infarction Simultaneously Associated With Aortic Mural Thrombosis Due to Essential Thrombocytosis.

Authors:  Sheng Ye; Wu-Jie Xia; Peng Chen
Journal:  Front Cardiovasc Med       Date:  2022-02-23

9.  What cardiologists should know about essential thrombocythemia and acute myocardial infarction: report of two cases and advanced heart failure therapies considerations.

Authors:  Marie-Camille Soucy-Giguère; Pierre Yves Turgeon; Mario Sénéchal
Journal:  Int Med Case Rep J       Date:  2019-08-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.